Literature DB >> 26775888

Percutaneous coronary intervention for nonagenarian patients with ST-segment elevation myocardial infarction: Experience of a single Japanese center.

Yukio Mizuguchi1, Sho Hashimoto2, Takeshi Yamada2, Norimasa Taniguchi2, Shunsuke Nakajima2, Tetsuya Hata2, Akihiko Takahashi2.   

Abstract

BACKGROUND: Old age is a prognostic risk factor for patients with ST elevation acute myocardial infarction (STEMI); however, few data exist describing STEMI patients aged over 90 years.
METHODS: We retrospectively evaluated the clinical indices and outcomes of 282 consecutive STEMI patients who underwent primary percutaneous coronary intervention (PCI) in our hospital between January 2008 and December 2012. Patients with acute myocardial infarction complicated by out-of-hospital cardiopulmonary arrest, patients with a left main trunk culprit lesion, and patients diagnosed more than 24h after symptom onset were excluded.
RESULTS: Of the patients treated during the study period, 11 (3.8%) were >90 years old. The mean door-to-balloon time was significantly longer for nonagenarians than younger patients (66.2 vs. 44.0minutes; p<0.001). This was mainly attributed to delays in decision-making regarding invasive treatment by both the doctors and families. Nonagenarians had multiple coronary artery stenoses more frequently (36.4% vs. 15.0%; p<0.05) and required intra-aortic balloon pumping more often (36.4% vs. 18.9%; p=0.15) compared with patients aged ≤89 years. However, the peak creatinine kinase levels and the left ventricular ejection fractions were similar between the groups. Moreover, the in-hospital and 30-day mortality rates were similar (9.1% vs. 4.6%, p=0.50; 9.1% vs. 3.6%, p=0.34, respectively) between the groups. The two-year survival rate was 81.8% in nonagenarians.
CONCLUSIONS: Despite the longer door-to-balloon time, higher use of intra-aortic balloon pumping, and larger number of diseased vessels, the 30-day and 2-year survival rates of nonagenarians with STEMI were comparable to those of younger patients.
Copyright © 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Nonagenarian; Percutaneous coronary intervention

Mesh:

Year:  2016        PMID: 26775888     DOI: 10.1016/j.jjcc.2015.12.002

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Managing Nonagenarians with Acute Myocardial Infarction: Invasive versus Conservative Treatment.

Authors:  Jooho Lee; Kyoung-Woo Seo; Jin-Sun Park; Hyoung-Mo Yang; Hong-Seok Lim; Byoung-Joo Choi; So-Yeon Choi; Myeong-Ho Yoon; Gyo-Seung Hwang; Seung-Jae Tahk; Joon-Han Shin
Journal:  Cardiol Res Pract       Date:  2020-11-10       Impact factor: 1.866

2.  Association of invasive treatment and lower mortality of patients ≥ 80 years with acute myocardial infarction: a propensity-matched analysis.

Authors:  Shuo-Lin Liu; Na-Qiong Wu; Meng Zhang; Jing-Lu Jin; Bing-Yang Zhou; Qian Dong; Jian-Jun Li
Journal:  J Geriatr Cardiol       Date:  2018-11       Impact factor: 3.327

3.  Comparison of Outcomes After Percutaneous Coronary Intervention in Elderly Patients, Including 10 628 Nonagenarians: Insights From a Japanese Nationwide Registry (J-PCI Registry).

Authors:  Yohei Numasawa; Taku Inohara; Hideki Ishii; Kyohei Yamaji; Shun Kohsaka; Mitsuaki Sawano; Masaki Kodaira; Shiro Uemura; Kazushige Kadota; Tetsuya Amano; Masato Nakamura
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

4.  Functional impairment and serum albumin predict in-hospital mortality in nonagenarians with acute infection: a retrospective cohort study.

Authors:  Wei Huang; Ying Sun; Yunli Xing; Cuiying Wang
Journal:  BMC Geriatr       Date:  2019-10-15       Impact factor: 3.921

5.  Primary percutaneous coronary intervention in nonagenarians: is it worthwhile?

Authors:  Mohammed M N Meah; Tobin Joseph; Wern Yew Ding; Matthew Shaw; Jonathan Hasleton; Nick D Palmer; Periaswamy Velavan; Suneil K Aggarwal
Journal:  BMC Cardiovasc Disord       Date:  2021-01-13       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.